Please assess the completion status of the following clinical trial:

Trial Title: Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically proven cutaneous melanoma, or clear cell sarcoma, which is considered as a subtype of melanoma.~2. Melanoma must be at one of the following AJCC 2002 stages:~   * Regional metastatic disease (any T; N2b, N2c or N3; M0).~  * Distant metastatic disease (any T; any N; M1a, M1b or M1c), except brain or leptomeningeal localizations, and except elevated LDH.~3. Patients must be HLA-A1.~4. Melanoma must express the MAGE-3 gene, as determined by RT-PCR.~5. Presence of at least one measurable or non-measurable tumor lesion, excluding leptomeningeal metastasis.~6. Expected survival of at least 3 months.~7. Karnofsky performance scale ≥70 or WHO performance status of 0 or 1.~8. Within the last 4 weeks prior to study day 1, vital laboratory parameters should be within normal range, except for the following laboratory parameters, which must be within the ranges specified:~   Lab Parameter Range~  * Hemoglobin ≥ 10 g/dl or ≥ 6,25 mmol/l~  * Granulocytes ≥ 1,500/µl~  * Lymphocytes ≥ 700/µl~  * Platelets ≥ 100,000/µl~  * Serum creatinine ≤ 2.0 mg/dl or ≤ 177 µmol/l~  * Serum bilirubin ≤ 2.0 mg/dl or ≤ 34.2 µmol/l~  * ASAT and ALAT ≤ 2 x the normal upper limits~  * LDH ≤ the normal upper limit.~9. Viral tests:~   * HIV (human immunodeficiency virus): negative antibodies.~  * HBV (hepatitis B virus): negative antigens; antibodies may be positive.~  * HCV (hepatitis C virus): negative antibodies.~10. Age ≥ 18 years.~11. Able and willing to give valid written informed consent.~Exclusion Criteria:~1. Previous treatment with more than one regimen of systemic chemotherapy, combined or not with non-specific immunotherapy such as interferon alpha or interleukins. Chemoimmunotherapy or radiotherapy must be stopped within the preceding 4 weeks (6 weeks for nitrosoureas and mitomycin C).~2. Previous treatment with a vaccine known or likely to contain the MAGE-3.A1 antigen, unless there is evidence that no CTL response against this antigen was induced by the vaccine.~3. Clinically significant heart disease i.e. NYHA class 3 congestive heart failure; myocardial infarction within the past six months; unstable angina; coronary angioplasty within the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias).~4. Active immunodeficiency or autoimmune disease. Vitiligo is not an exclusion criterion.~5. Other serious acute or chronic illnesses, e.g. active infections requiring antibiotics, bleeding disorders, or other conditions requiring concurrent medications not allowed during this study.~6. Other malignancy within 3 years prior to entry into the study, except for treated non-melanoma skin cancer and cervical carcinoma in situ.~7. Lack of availability for immunological and clinical follow-up assessments.~8. Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment.~9. Pregnancy or breastfeeding.~10. Women of childbearing potential: Refusal or inability to use effective means of contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MAGE-3.A1 Peptide mixed with CpG 7909 (Type: EXPERIMENTAL): Patients were vaccinated every two weeks on six occasions. On each vaccination day, the MAGE-3.A1 peptide (300 mcg) mixed with CpG 7909 (5 mg) was administered twice intradermally (10% of the dose each) and twice subcutaneously (40% of the dose each) in the arms and thighs.

Based on this trial design, predict the completion outcome and termination type (if applicable).